MARISA ZITO: Open Payments
NPI 1972252047 · FERNDALE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,496 in 50 payments from 14 companies in 2025. Trend: 2023 $721 · 2024 $968 · 2025 $1,496
Food & beverage: $1,496
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $256 |
| Lundbeck LLC | 5 | $213 |
| Vanda Pharmaceuticals Inc. | 4 | $197 |
| ABBVIE INC. | 11 | $195 |
| Neurocrine BioSciences, Inc. | 3 | $145 |
| Otsuka America Pharmaceutical, Inc. | 8 | $141 |
| Supernus Pharmaceuticals, Inc. | 1 | $125 |
| Tris Pharma Inc | 3 | $67 |
| Collegium Pharmaceutical, Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $37 |
Products named: CAPLYTA, REXULTI, VRAYLAR, FANAPT, INGREZZA, Qelbree, Dyanavel XR, ABILIFY ASIMTUFII.
Industry payments across MI — which companies pay providers there.
